PCN5 COST-UTILITY ANALYSIS OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (EBC): A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE
- 31 December 2004
- journal article
- abstracts
- Published by Elsevier in Value in Health
- Vol. 7 (6) , 670
- https://doi.org/10.1016/s1098-3015(10)65739-7
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: